Group 1 - The core point of the news is that Junshi Biosciences (688180.SH) is currently experiencing a decline in stock price, closing at 35.03 yuan with a drop of 1.93% [1] - Junshi Biosciences was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 15, 2020, with an initial issuance of 87.13 million shares at a price of 55.50 yuan per share [1] - The stock reached its highest point at 220.40 yuan on the first day of trading but is now in a state of decline [1] Group 2 - In 2020, Junshi Biosciences raised a total of 4.836 billion yuan from its initial public offering, with a net amount of 4.497 billion yuan after deducting issuance costs [1] - The company initially planned to raise 2.7 billion yuan, which was exceeded by 1.797 billion yuan [1] - The total fundraising amount from the company's specific issuance of A-shares in 2022 was approximately 3.7765 billion yuan, with a net amount of about 3.7448 billion yuan after fees [2] - The total amount raised by Junshi Biosciences from both fundraising rounds is 8.612 billion yuan [2]

Core Viewpoint - Junshi Biosciences has established a new subsidiary in Shanghai with a registered capital of 500 million yuan, indicating its ongoing expansion and investment in biotechnology [1] Group 1 - The newly established subsidiary is named Shanghai Junyile Biotechnology Co., Ltd. [1] - The registered capital of the new company is 500 million yuan [1] - The business scope of the subsidiary includes technology services, development, consulting, exchange, transfer, promotion, import and export of goods and technology, as well as information consulting services (excluding licensed information consulting services) [1] Group 2 - Junshi Biosciences holds 100% ownership of the new subsidiary [1]

Group 1 - The core point of the article is that Junshi Biosciences (688180.SH) announced that its controlling shareholder and chairman, Mr. Xiong Jun, has cumulatively increased his holdings of the company's A-shares by 100,000 shares, representing approximately 0.01% of the total share capital, with a total transaction amount of RMB 3.8384 million [1] - The share purchase was conducted through the Shanghai Stock Exchange system via centralized bidding [1] - The increase plan has not yet been fully implemented, and Mr. Xiong Jun will continue to increase his holdings of the company's shares opportunistically during the implementation period of the increase plan [1]

Core Viewpoint - The chairman of Junshi Biosciences, Xiong Jun, plans to increase his stake in the company by at least RMB 100 million over the next 12 months, starting from April 12, 2025, through various trading methods [1] Group 1: Shareholding Plan - Xiong Jun intends to increase his holdings in both A-shares and H-shares, with a minimum of RMB 50 million allocated for A-shares [1] - As of the announcement date, Xiong Jun has already acquired 100,000 A-shares, representing approximately 0.01% of the company's total share capital, with a total transaction amount of RMB 3.8384 million [1] - The share acquisition plan is still in progress, and Xiong Jun will continue to purchase shares according to the outlined plan during the implementation period [1]

Core Viewpoint - Junshi Biosciences (01877) announced that its controlling shareholder and chairman, Mr. Xiong Jun, has increased his shareholding in the company through the Shanghai Stock Exchange, acquiring a total of 100,000 A-shares, which represents approximately 0.01% of the company's total share capital, with a total transaction amount of RMB 3.8384 million. The share acquisition plan is not yet completed, and Mr. Xiong will continue to increase his holdings as per the plan during the implementation period [1]. Summary by Categories - Shareholding Increase: Mr. Xiong Jun has cumulatively acquired 100,000 A-shares, amounting to 0.01% of the total share capital of Junshi Biosciences [1]. - Transaction Details: The total amount spent on this share acquisition is RMB 3.8384 million [1]. - Future Plans: The share acquisition plan is still ongoing, and Mr. Xiong intends to continue purchasing shares in accordance with the related plan [1].

Group 1 - The core point of the article is that Junshi Biosciences (01877) announced that its controlling shareholder and chairman, Mr. Xiong Jun, has increased his shareholding in the company [1] - Mr. Xiong Jun has cumulatively acquired 100,000 A-shares through the Shanghai Stock Exchange, representing approximately 0.01% of the company's total share capital [1] - The total transaction amount for this share acquisition is approximately RMB 3.8384 million [1] Group 2 - The share acquisition plan is not yet fully implemented, and Mr. Xiong Jun intends to continue purchasing shares in accordance with the relevant plan during the implementation period [1]

格隆汇2月10日丨君实生物(01877.HK)公告，上海君实生物医药科技股份有限公司控股股东、实际控制 人之一兼董事长熊俊拟自2025年4月12日起12个月内，通过上海证券交易所交易系统与香港联合交易所 有限公司允许的方式(包括但不限于集中竞价和大宗交易等方式)增持公司A股股份及H股股份，合计增 持金额不低于人民币1亿元，其中A股增持金额不低于人民币5,000万元。 截至本公告披露日，熊俊通过上海证券交易所系统以集中竞价方式累计增持公司A股股份10万股，约占 公司总股本的0.01%，累计成交总额为人民币383.84万元。本次增持计划尚未实施完毕，熊俊将继续按 照相关增持计划，在增持计划实施期间内择机增持公司股份。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 茲載列上海君實生物醫藥科技股份有限公司在上海證券交易所網站刊發之《上海 君實生物醫藥科技股份有限公司關於控股股東、實際控制人之一兼董事長增持股 份進展公告》，僅供參閱。 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2026年2月10日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 * 僅供識別之用 （股份代號：1877） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 证券代码：688180 证券简称：君实生 ...

上海君实生物医药科技股份有限公司 关于控股股东、实际控制人之一兼董事长 增持股份进展公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 证券代码：688180 证券简称：君实生物 公告编号：临 2026-004 重要内容提示： 上海君实生物医药科技股份有限公司（以下简称"公司"）控股股东、 实际控制人之一兼董事长熊俊先生拟自 2025 年 4 月 12 日起 12 个月内，通过上 海证券交易所交易系统与香港联合交易所有限公司允许的方式（包括但不限于集 中竞价和大宗交易等方式）增持公司 A 股股份及 H 股股份，合计增持金额不低 于人民币 1 亿元，其中 A 股增持金额不低于人民币 5,000 万元。 截至本公告披露日，熊俊先生通过上海证券交易所系统以集中竞价方式 累计增持公司 A 股股份 100,000 股，约占公司总股本的 0.01%，累计成交总额为 人民币 383.84 万元。本次增持计划尚未实施完毕，熊俊先生将继续按照相关增 持计划，在增持计划实施期间内择机增持公司股份。 本次增持计划可能存在因资本市场 ...

格隆汇2月10日丨君实生物(688180.SH)公布，截至本公告披露日，控股股东、实际控制人之一兼董事长 熊俊先生通过上海证券交易所系统以集中竞价方式累计增持公司A股股份10万股，约占公司总股本的 0.01%，累计成交总额为人民币383.84万元。本次增持计划尚未实施完毕，熊俊先生将继续按照相关增 持计划，在增持计划实施期间内择机增持公司股份。 ...